Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line.

Lupo MG, Biancorosso N, Brilli E, Tarantino G, Adorni MP, Vivian G, Salvalaio M, Dall'Acqua S, Sut S, Neutel C, Chen H, Bressan A, Faggin E, Rattazzi M, Ferri N.

Nutrients. 2020 Feb 9;12(2). pii: E436. doi: 10.3390/nu12020436.

2.

Browning Effects of a Chronic Pterostilbene Supplementation in Mice Fed a High-Fat Diet.

La Spina M, Galletta E, Azzolini M, Gomez Zorita S, Parrasia S, Salvalaio M, Salmaso A, Biasutto L.

Int J Mol Sci. 2019 Oct 29;20(21). pii: E5377. doi: 10.3390/ijms20215377.

3.

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.

Rigon L, Salvalaio M, Pederzoli F, Legnini E, Duskey JT, D'Avanzo F, De Filippis C, Ruozi B, Marin O, Vandelli MA, Ottonelli I, Scarpa M, Tosi G, Tomanin R.

Int J Mol Sci. 2019 Apr 24;20(8). pii: E2014. doi: 10.3390/ijms20082014.

4.

FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).

Bellesso S, Salvalaio M, Lualdi S, Tognon E, Costa R, Braghetta P, Giraudo C, Stramare R, Rigon L, Filocamo M, Tomanin R, Moro E.

Hum Mol Genet. 2018 Jul 1;27(13):2407. doi: 10.1093/hmg/ddy208. No abstract available.

PMID:
29917101
5.

Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells.

Catanzaro D, Nicolosi S, Cocetta V, Salvalaio M, Pagetta A, Ragazzi E, Montopoli M, Pasut G.

Oncotarget. 2018 Mar 30;9(24):16847-16860. doi: 10.18632/oncotarget.24708. eCollection 2018 Mar 30.

6.

FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).

Bellesso S, Salvalaio M, Lualdi S, Tognon E, Costa R, Braghetta P, Giraudo C, Stramare R, Rigon L, Filocamo M, Tomanin R, Moro E.

Hum Mol Genet. 2018 Jul 1;27(13):2262-2275. doi: 10.1093/hmg/ddy131. Erratum in: Hum Mol Genet. 2018 Jul 1;27(13):2407.

PMID:
29648648
7.

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model.

Salvalaio M, D'Avanzo F, Rigon L, Zanetti A, D'Angelo M, Valle G, Scarpa M, Tomanin R.

Int J Mol Sci. 2017 May 17;18(5). pii: E1072. doi: 10.3390/ijms18051072.

8.

Perturbations in cell signaling elicit early cardiac defects in mucopolysaccharidosis type II.

Costa R, Urbani A, Salvalaio M, Bellesso S, Cieri D, Zancan I, Filocamo M, Bonaldo P, Szab├▓ I, Tomanin R, Moro E.

Hum Mol Genet. 2017 May 1;26(9):1643-1655. doi: 10.1093/hmg/ddx069.

PMID:
28334757
9.

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.

Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, Marin O, Vandelli MA, Forni F, Scarpa M, Tomanin R, Tosi G.

PLoS One. 2016 May 26;11(5):e0156452. doi: 10.1371/journal.pone.0156452. eCollection 2016.

10.

Glucocerebrosidase deficiency in zebrafish affects primary bone ossification through increased oxidative stress and reduced Wnt/╬▓-catenin signaling.

Zancan I, Bellesso S, Costa R, Salvalaio M, Stroppiano M, Hammond C, Argenton F, Filocamo M, Moro E.

Hum Mol Genet. 2015 Mar 1;24(5):1280-94. doi: 10.1093/hmg/ddu538. Epub 2014 Oct 17.

PMID:
25326392
11.

Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment.

Mazzoccoli G, Tomanin R, Mazza T, D'Avanzo F, Salvalaio M, Rigon L, Zanetti A, Pazienza V, Francavilla M, Giuliani F, Vinciguerra M, Scarpa M.

BMC Med Genomics. 2013 Oct 2;6:37. doi: 10.1186/1755-8794-6-37.

Supplemental Content

Loading ...
Support Center